GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science, leading to the development of new medicines.
Nexavar Approved for Treatment of Liver Cancer in China
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar® (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer.
Nexavar Study Demonstrates Significant Improvement in Overall Survival
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that The New England Journal of Medicine published landmark results of a Nexavar study in liver cancer. The data of the Phase III trial showed that Nexavar® (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo.
Pfizer Reports Second-Quarter 2008 Results
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) reported financial results for the second-quarter 2008. The Company recorded revenues of $12.1 billion, an increase of 9% compared with $11.1 billion in the year-ago quarter. In the U.S., revenues were $4.8 billion, a decrease of 2%, while international revenues were $7.4 billion, an increase of 18%. Revenues reflect the positive impact of foreign exchange, which increased revenues by approximately $800 million or 7%, as well as the solid performance of many key products.
GlaxoSmithKline teams up with academia to develop new medicines of value
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) is launching a ground-breaking new concept which will tap into the highest quality thinking in academia to optimise the early clinical development of new GSK medicines in a model of shared risk and reward.
Novartis gains momentum with strong performance in first half of 2008
- Details
- Category: Novartis
- First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics
- Net sales rise 11% (+2% in local currencies) to USD 20.6 billion
- Operating income advances 12% to USD 4.9 billion on business expansion, productivity gains and currency benefits
Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the second quarter ended June 30, 2008.
- Diluted earnings per share, excluding specified items, were $0.84, above Abbott's previously announced guidance range of $0.78 to $0.80, reflecting 21.7 percent growth. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.85, up 34.9 percent.
More Pharma News ...
- Boehringer Ingelheim FENS Award for exceptional research in neuroscience
- Novartis completes acquisition of 25% stake in Alcon from Nestlé
- Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows
- Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
- Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million
- Summary Judgment Granted for SEROQUEL Patent Litigation in the US
- GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval